
FDA Fast Tracks Antibody Therapy for Pulmonary Infections Including Cystic Fibrosis
Clarametyx Biosciences said its investigational antibody therapy, CMTX-101, which is in a phase 1b/2a study, remains on track for full trial enrollment by the end of 2025.


























